Alpl-1 is a target for chimeric antigen receptor therapy in osteosarcoma

dc.contributor.author	Mensali, Nadia
dc.contributor.author	Koeksal, Hakan
dc.contributor.author	Joaquina, Sandy
dc.contributor.author	Rodríguez González, René
dc.date.accessioned	2023-10-25T08:54:20Z
dc.date.available	2023-10-25T08:54:20Z
dc.date.issued	2023
dc.identifier.citation	Nature Communications, 14(1) (2023); doi:10.1038/s41467-023-39097-x
dc.identifier.uri	https://hdl.handle.net/10651/69855
dc.description.sponsorship	This body of the European Union receives support from the European Union’s Horizon 2021 research and innovation program. C.P. is supported by a PFIS fellowship from Instituto de Salud Carlos III (ISCIII)(FI21/00161). Figures 3a, 3e, 4a, ad Supplementary Fig. 4a were prepared using BioRender.com
dc.description.statementofresponsibility	Mensali N., Köksal H., Joaquina S., Wernhoff P., Casey N.P., Romecin P., Panisello C., Rodriguez R.
dc.language.iso	eng
dc.relation.ispartof	Nature Communications
dc.rights	© The Author(s) 2023
dc.rights	CC Reconocimiento 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/
dc.source	WOS:001047512000030
dc.title	Alpl-1 is a target for chimeric antigen receptor therapy in osteosarcoma
dc.type	journal article
dc.identifier.doi	10.1038/s41467-023-39097-x
dc.relation.projectID	FI21/00161
dc.relation.publisherversion	http://dx.doi.org/10.1038/s41467-023-39097-x
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Artículos [36261]
Investigaciones y Documentos OpenAIRE [7903]
Publicaciones resultado de proyectos financiados con fondos públicos
Medicina [934]

Este ítem está sujeto a una licencia Creative Commons